NCT00818480View on ClinicalTrials.gov

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

August 31, 2012

Conditions
Prostate CancerMelanomaNon-Hodgkin's Lymphoma
Interventions
DRUG

YM155

continuous infusion

Trial Locations (3)

78229

Institute for Drug Development, San Antonio

South Texas Accelerated, San Antonio

84112

Huntsman Cancer Hospital, Salt Lake City

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY